Rhenman & Partners Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.75M	Sell	59,900 -33,000	-36%	-$2.48M	0.45%	73
2026 Q1	$6.98M	Sell	92,900 -65,600	-41%	-$5.18M	0.86%	48
2025 Q4	$12.5M	Sell	158,500 -151,500	-49%	-$11.4M	1.17%	34
2025 Q3	$20.3M	Buy	310,000 +128,000	+70%	+$6.25M	2.24%	12
2025 Q2	$7.19M	Buy	182,000 +101,000	+125%	+$3.31M	0.91%	39
2025 Q1	$2.44M	Sell	81,000 -131,500	-62%	-$4.31M	0.28%	65
2024 Q4	$7.43M	Buy	212,500 +17,500	+9%	+$654K	0.76%	47
2024 Q3	$7.81M	Buy	195,000 +65,000	+50%	+$3.02M	0.63%	52
2024 Q2	$6.2M	Buy	+130,000	New	+$5.33M	0.59%	47
2023 Q1	–	Sell	-50,000	Closed	-$1.89M	–	89
2022 Q4	$1.89M	Hold	50,000	–	–	0.2%	84
2022 Q3	$2.21M	Hold	50,000	–	–	0.23%	83
2022 Q2	$1.85M	Sell	50,000 -21,000	-30%	-$792K	0.21%	81
2022 Q1	$2.63M	Sell	71,000 -4,000	-5%	-$131K	0.26%	81
2021 Q4	$2.29M	Hold	75,000	–	–	0.15%	87
2021 Q3	$2.52M	Hold	75,000	–	–	0.18%	85
2021 Q2	$2.99M	Hold	75,000	–	–	0.2%	88
2021 Q1	$3.37M	Buy	+75,000	New	+$4.18M	0.24%	83
2016 Q2	–	Sell	-64,000	Closed	-$2.59M	–	98
2016 Q1	$2.59M	Sell	64,000 -3,000	-4%	-$122K	0.51%	66
2015 Q4	$4.15M	Sell	67,000 -13,000	-16%	-$701K	0.63%	57
2015 Q3	$3.23M	Sell	80,000 -14,000	-15%	-$725K	0.52%	61
2015 Q2	$5.41M	Sell	94,000 -8,000	-8%	-$509K	0.65%	53
2015 Q1	$6.49M	Buy	102,000 +60,000	+143%	+$4.07M	1.1%	33
2014 Q4	$2.59M	Sell	42,000 -16,000	-28%	-$790K	0.75%	55
2014 Q3	$2.25M	Buy	58,000 +22,000	+61%	+$780K	0.66%	56
2014 Q2	$1.24M	Buy	+36,000	New	+$1.13M	0.37%	83

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Rhenman & Partners Asset Management's IONS Position: Q2 2026 in Review

Rhenman & Partners Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 36% in Q2 2026, selling an estimated $2.48M and leaving 59,900 shares worth $4.75M. The position accounts for 0.45% of the portfolio, ranked #73.

Rhenman & Partners Asset Management first reported a position in IONS in Q2 2014 and has held it in 25 quarters since. The position peaked at $20.3M in Q3 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Rhenman & Partners Asset Management held 59,900 shares of Ionis Pharmaceuticals worth $4.75M as of Q2 2026.
Rhenman & Partners Asset Management sold 33,000 Ionis Pharmaceuticals shares in Q2 2026, an estimated $2.48M.
Ionis Pharmaceuticals made up 0.45% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #73 holding.
Rhenman & Partners Asset Management first reported a position in Ionis Pharmaceuticals in Q2 2014 and has held it in 25 quarters since.
Rhenman & Partners Asset Management's Ionis Pharmaceuticals position peaked at $20.3M in Q3 2025.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.